

Nr. Crt.	Nume	Status	Locatie
1	Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer (monarchE)	Activ, inca nu recruteaza	<p>Centrul de Oncologie Sf. Nectarie SRL Craiova, Dolj, Romania, 200347</p> <p>S.C. R.T.C. Radiology Therapeutic Center S.R.L. Otopeni, Ilfov, Romania, 075100</p> <p>SC Oncopremium Team SRL Baia Mare, Maramures, Romania, 430291</p> <p>Institutul Oncologic Dr TrestioreanuBucuresti Bucuresti, Sector 2, Romania, 022328</p> <p>Spitalul Clinic Filantropia Bucuresti, Romania, 011171</p> <p>Institutul Oncologic "Prof. Dr. Ion Chiricuta" Cluj-Napoca Cluj-Napoca, Romania, 400015</p> <p>Spitalul Clinic Judetean de UrgentaSf.Apostol Andrei Constanta Constanta, Romania, 900591</p>
2	Study of Nivolumab Versus Placebo in Participants With High-Risk Breast Cancer (CheckMate 7FL)	In curs de recrutare	<p>Local Institution Not yet recruiting Bucharest, Romania, 011171 Contact: Site 0029</p> <p>Local Institution Not yet recruiting Bucuresti, Romania, 022328 Contact: Site 0025</p> <p>Local Institution Not yet recruiting Craiova, Romania, 200347 Contact: Site 0028</p> <p>Local Institution Not yet recruiting Floresti, Romania, 407280 Contact: Site 0027</p> <p>Local Institution Not yet recruiting Suceava, Romania, 720237 Contact: Site 0026</p>
3	Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.	Activ, inca nu recruteaza	<p>Novartis Investigative Site Floresti, Cluj, Romania, 407280</p> <p>Novartis Investigative Site Bucuresti, Romania, 011171</p> <p>Novartis Investigative Site Bucuresti, Romania, 030463</p> <p>Novartis Investigative Site Craiova, Romania, 200347</p>

	(SOLAR-1)		Novartis Investigative Site Iasi, Romania , 700483 Novartis Investigative Site Timisoara, Romania , 300219	
4	A European Registry Study to Prospectively Observe Treatment Patterns and Outcomes in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced (LA) or Metastatic Breast Cancer (mBC) (SAMANTHA)	Activ, inca nu recruteaza	County Hospital Alba; Oncology Alba Iulia, Romania , 510073 "Filantropia" Clinical Hospital; Gynecological Oncology Bucharest, Romania , 011191 Institutul Oncologic Prof. Dr. Al. TrestioreanuBucuresti Bucuresti, Romania , 022328 Prof. Dr. I. Chiricuta Institute of Oncology Cluj Napoca, Romania , 400015 Cluj-Napoca Emergency Clinical County Hospital; Medical Oncology Cluj-Napoca, Romania , 400006 Centrul de OncologieSfantulNectarie Craiova, Romania , 200347 Oncomed SRL Timisoara, Romania , 300239	
5	A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer	Activ, inca nu recruteaza	S.C. Centrul de Oncologie Sf. Nectarie S.R.L. /ID# 124948 Craiova, Dolj, Romania , 200347 Institutul Oncologic Trestiore /ID# 124943 Bucharest, Romania , 022328 Spitalul Clinic Judetean de Urgenta /ID# 124945 Cluj, Romania , 400006 Oncomed SRL /ID# 127598 Timisoara, Romania , 300239	
6	A Study Of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer.	In curs de recrutare	"Filantropia" Clinical Hospital; Gynecological Oncology Bucharest, Romania , 011191 Institute of Oncology "Prof. Dr. I. Chiricuta" Cluj-Napoca, Romania , 400015 Oncology Center Sf. Nectarie Craiova, Romania , 200347 Centrul de OncologieOncohelp Timisoara, Romania , 300239	Not yet recruiting Not yet recruiting Not yet recruiting Not yet recruiting
7	A Randomized Study of AZD2014 in Combination With Fulvestrant in Metastatic or Advanced Breast Cancer	Activ, inca nu recruteaza	Center of Oncology Euroclinic Bucharest, Romania Oncology Center Sf Nectarie Caracal, Romania Cluj County Clinical Emergency Hospital, Clinical Department of Medical Oncology Cluj-Napoca, Romania Oncology Institute "Prof. Dr. Ion Chiricuta" Cluj-Napoca, Romania Oncology Center Oncolab Craiova Craiova, Romania	
8	A Study of Trastuzumab Emtansine (Kadcyla) Plus	Activ, inca nu recruteaza	Institutul Oncologic Prof. Dr. Al. TrestioreanuBucuresti Bucuresti, Romania , 022328	

	Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer		<p>Prof. Dr. I. Chiricuta Institute of Oncology Cluj Napoca, Romania, 400015</p> <p>Cluj Clinical County Hospital; Oncology Dept Cluj-Napoca, Romania, 400006</p> <p>Regional Institute of Oncology Iasi Iasi, Romania, 700483</p>
9	A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer	Activ, inca nu recruteaza	<p>Emergency University Bucharest Hospital; Oncology Department Bucharest, Romania, 050098</p> <p>Prof. Dr. I. Chiricuta Institute of Oncology Cluj Napoca, Romania, 400015</p> <p>Oncology Inst. Cluj-Napoca; Cancer Dept Cluj-Napoca, Romania, 400015</p> <p>Euroclinic Center of Oncology SRL Iasi, Romania, 700106</p>
10	A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer.	Activ, inca nu recruteaza	<p>Research Site Braila, Romania, 810325</p> <p>Research Site Craiova, Romania, 200347</p> <p>Research Site Onesti, Romania, 601048</p> <p>Research Site Timisoara, Romania, 300239</p>
11	A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer	In curs de recrutare	<p>"Filantropia" Clinical Hospital; Gynecological Oncology Bucharest, Romania, 011191</p> <p>Institutul Oncologic Prof. Dr. Al. Trestioreanu Bucuresti Bucuresti, Romania, 022328</p> <p>Institutul Oncologic Prof. Dr. Ion Chiricuta Cluj Napoca; Oncologie Medicala Cluj Napoca, Romania, 400015</p> <p>Centrul de Oncologie Sfantul Nectarie Craiova, Romania, 200347</p>
12	Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)	Activ, inca nu recruteaza	<p>Spitalul Clinic CF nr.2 Bucuresti Bucharest, Romania, 011464</p> <p>Spitalul Municipal Ploiesti Ploiesti, Romania, 100337</p> <p>Spitalul Judetean de Urgente "Sf. Ioanel Nou" Suceava, Romania, 720237</p> <p>Spitalul Clinic Judetean Mures Tg Mures, Romania, 540142</p>
13	A Study of Taselisib + Fulvestrant Versus	Activ, inca nu recruteaza	<p>Institut of Oncology Al. Trestioreanu Bucharest; Oncology Department Bucuresti, Romania, 022328</p>

	Placebo + Fulvestrant in Participants With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy		<p>Prof. Dr. I. Chiricuta Institute of Oncology Cluj Napoca, Romania, 400015</p> <p>Oncology Center Sf. Nectarie Craiova, Romania, 200347</p> <p>Euroclinic Center of Oncology SRL Iasi, Romania, 700106</p>
14	PAKT: AZD5363 in Combination With Paclitaxel in Triple-Negative Advanced or Metastatic Breast Cancer	Activ, inca nu recruteaza	<p>Prof. Dr. I. Chiricuta Oncology Institute Cluj-Napoca, Romania</p> <p>Sf. Nectarie SRL Oncologie Medical Center Craiova, Romania</p> <p>Center of Oncology Euroclinic Iasi, Romania</p>
15	A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)	Activ, inca nu recruteaza	<p>Prof. Dr. I. Chiricuta Institute of Oncology Cluj Napoca, Romania, 400015</p> <p style="text-align: right;">Active, not recruiting</p> <p style="text-align: center;">Centrul de OncologieSfantulNectarie Craiova, Romania, 200347</p> <p style="text-align: right;">Active, not recruiting</p>
16	Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.	Activ, inca nu recruteaza	<p>Research Site Bucharest, Romania, 013811</p> <p>Research Site Bucuresti, Romania, 011171</p> <p>Research Site Bucuresti, Romania, 030171</p> <p>Research Site Cluj Napoca, Romania, 400015</p> <p>Research Site Cluj-Napoca, Romania, 400015</p>
17	A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer	Activ, inca nu recruteaza	For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
18	A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer	Activ, inca nu recruteaza	<p>Novartis Investigative Site Bucharest, Romania, 050098</p> <p>Novartis Investigative Site Bucuresti, Romania, 022328</p> <p>Novartis Investigative Site Timisoara, Romania, 300239</p>

19	ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D	Activ, inca nu recruteaza	<p>Novartis Investigative Site Bucharest, Romania, 022328</p> <p>Novartis Investigative Site Bucharest, Romania, 050098</p> <p>Novartis Investigative Site Bucuresti, Romania, 022328</p> <p>Novartis Investigative Site Cluj-Napoca, Romania, 400015</p> <p>Novartis Investigative Site Iasi, Romania, 700106</p>
20	A Study of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as Initial Treatment for Participants With Triple-Negative Breast Cancer That Has Spread	Activ, inca nu recruteaza	<p>Prof. Dr. I. Chiricuta Institute of Oncology Cluj Napoca, Romania, 400015</p> <p>Oncology Center Sf. Nectarie Craiova, Romania, 200347</p>
21	A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130)	Activ, inca nu recruteaza	<p>Oncomed SRL Timisoara, Romania, 300239</p>
22	A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer (NATALEE)	In curs de recrutare	<p>Novartis Investigative Site Craiova, Dolj, Romania, 200347</p> <p>Novartis Investigative Site Craiova, Dolj, Romania, 200535</p> <p>Novartis Investigative Site Bucuresti, Romania, 010991</p> <p>Novartis Investigative Site Bucuresti, Romania, 011171</p> <p>Novartis Investigative Site Cluj-Napoca, Romania, 400124</p> <p>Novartis Investigative Site Iasi, Romania, 700106</p> <p>Novartis Investigative Site Timisoara, Romania, 300239</p>
23	A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab	Inca nu recruteaza	<p>Institutul Oncologic Prof. Dr. Ion Chiricuta Cluj-Napoca, Cluj, Romania, 400015 Contact: Principal Investigator</p>

	Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)		<p>Onco Clinic Consult SA Craiova, Dolj, Romania, 200103 Contact: Principal Investigator</p> <p>Centrul de Oncologie Sfantu Nectarie Craiova, Dolj, Romania, 200347 Contact: Principal Investigator</p> <p>Institutul Oncologic Bucuresti IOB Bucharest, Romania, 22328 Contact: Principal Investigator</p>
24	Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer	In curs de recrutare	<p>Research Site Recruiting Bucharest, Romania, 022328</p> <p>Research Site Recruiting Bucharest, Romania, 022338</p> <p>Research Site Recruiting Bucharest, Romania, 030171</p> <p>Research Site Recruiting Cluj Napoca, Romania, 400015</p> <p>Research Site Recruiting Iasi, Romania, 700483</p> <p>Research Site Recruiting Ploiesti, Romania, 100337</p> <p>Research Site Recruiting Timisoara, Romania, 300239</p>